Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025 telehealth gold rush, the company is currently navigating a period of intense volatility. After a meteoric rise fueled by [...]
As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain View giant is currently navigating a high-stakes transition from a search-engine powerhouse to an "AI-first" agentic platform. The company is currently in focus following a blockbuster [...]
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna’s proprietary circular RNA (oRNA)
The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP National Employment Report "NER Pulse" data, released throughout the month, has revealed four consecutive weeks
Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.
The global pharmaceutical landscape underwent a seismic shift today, February 24, 2026, as the two pioneers of the weight loss drug revolution reported vastly different outlooks for the coming year. While Eli Lilly and Co. (LLY:NYSE) raised its 2026 revenue guidance to record-breaking levels, its primary rival, Novo Nordisk
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4 2025 earnings beat, showcasing the immense scaling power of its telehealth platform. On the other, the company is embroiled in [...]
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as […]
Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
